Aarti Pharmalabs Ltd - 543748 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 and 47 of SEBI Listing Regulations, we hereby enclose Newspaper Publication of Standalone & Consolidated Financial Results for the quarter and year ended March 31, 2023 Aarti Pharmalabs Ltd - 543748 - Related Party Transaction For The Half Year Ended March 31, 2023.
Related Party Transaction for the half year ended March 31, 2023. Aarti Pharmalabs Ltd - 543748 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Appointment of Statutory Auditor Aarti Pharmalabs Ltd - 543748 - Results Financial Results For March 31,2023
Audited Financial Results (Standalone and Consolidated) for Quarter and Year Ended March 31, 2023. Aarti Pharmalabs Ltd - 543748 - Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting held on May 12,2023 Aarti Pharmalabs Ltd - 543748 - Board Meeting Intimation for Meeting Scheduled To Be Held On Friday, May 12, 2023.
Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2023 ,inter alia, to consider and approve - Audited Financial Results for the quarter ended March 31, 2023 and Audited Financial Statements for the year ended March 31, 2023 - Any other business matter, if required, with the permission of Chair Aarti Pharmalabs Ltd - 543748 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyAarti Pharmalabs Ltd 2CIN NO.U24100GJ2019PLC110964 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Nikhil Natu Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Piyush Lakhani Designation: Chief Financial Officer EmailId: [email protected] Date: 24/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Aarti Pharmalabs Ltd - 543748 - Reply To Clarification Sought With Respect To Significant Movement In Price Of Company'S Security At BSE Limited
Reply to clarification sought with respect to significant movement in price of Company's security at BSE Limited Aarti Pharmalabs Ltd - 543748 - Clarification sought from Aarti Pharmalabs Ltd
The Exchange has sought clarification from Aarti Pharmalabs Ltd on April 18, 2023 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.